 The endpoint, Deborah, is a measure of efficacy. So how does the drug work and what can we measure in a clinical trial? So in this situation, as was pointed out, the current endpoint really revolves around is the organ being rejected? Is there rejection that is occurring? What we want to do is change it to an endpoint where we're looking at the health of the kidney and the immune response to the kidney.